- Home
- UNCY vs SGMT Comparison
UNCY vs SGMT Comparison
Compare UNCY & SGMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | UNCY | SGMT |
|---|---|---|
| Founded | 2016 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 150.1M | 169.4M |
| IPO Year | 2021 | 2021 |
Fundamental Metrics
Financial Performance| Metric | UNCY | SGMT |
|---|---|---|
| Price | $5.29 | $10.59 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 8 |
| Target Price | $25.67 | ★ $26.13 |
| AVG Volume (30 Days) | 700.4K | ★ 1.4M |
| Earning Date | 05-13-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | N/A |
| Revenue | $675,000.00 | ★ $2,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $582.86 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.72 | $4.50 |
| 52 Week High | $8.74 | $11.15 |
Technical Indicators
Market Signals| Indicator | UNCY | SGMT |
|---|---|---|
| Relative Strength Index (RSI) | 48.13 | 67.13 |
| Support Level | $5.28 | $6.55 |
| Resistance Level | $5.86 | $11.15 |
| Average True Range (ATR) | 0.25 | 0.59 |
| MACD | 0.04 | 0.01 |
| Stochastic Oscillator | 46.29 | 70.67 |
Price Performance
Historical ComparisonAbout UNCY Unicycive Therapeutics Inc.
Unicycive Therapeutics Inc is a clinical-stage biotechnology company focused on identifying, developing, and commercializing therapies to address unmet medical needs, with a primary focus on kidney disease. The company is advancing two key product candidates: oxylanthanum carbonate (OLC), a phosphate binder for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis, and UNI-494, a drug candidate for the treatment of acute kidney injury.
About SGMT Sagimet Biosciences Inc. Series A
Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.